| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-10-2921 |
| P698 | PubMed publication ID | 21531812 |
| P2093 | author name string | Yaping Sun | |
| Yan Lan | |||
| Stephen D Gillies | |||
| Kin-Ming Lo | |||
| Stefan O Mueller | |||
| Thore Hettmann | |||
| Beatrice Brunkhorst | |||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3673-3685 | |
| P577 | publication date | 2011-04-29 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity | |
| P478 | volume | 17 |
| Q92965479 | A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control |
| Q35266959 | An artificial antigen-presenting cell with paracrine delivery of IL-2 impacts the magnitude and direction of the T cell response. |
| Q60949713 | Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy |
| Q51786117 | Antibody-cytokine fusion proteins for cancer immunotherapy: an update on recent developments. |
| Q93129949 | Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation |
| Q35212575 | Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution |
| Q55316979 | Beyond checkpoint inhibition - Immunotherapeutical strategies in combination with radiation. |
| Q37741534 | Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. |
| Q33811204 | Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy |
| Q36696647 | Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy |
| Q37637949 | Current and Potential Uses of Immunocytokines as Cancer Immunotherapy |
| Q96303542 | Cytokines that target immune killer cells against tumors |
| Q38017203 | Designing immunoconjugates for cancer therapy |
| Q61443377 | Directed evolution of super-secreted variants from phage-displayed human Interleukin-2 |
| Q57911948 | Emerging classes of armed antibody therapeutics against cancer |
| Q55162750 | Flexible Macromolecule versus Rigid Particle Retention in the Injected Skin and Accumulation in Draining Lymph Nodes Are Differentially Influenced by Hydrodynamic Size. |
| Q91868537 | Human and murine IL2 receptors differentially respond to the human-IL2 component of immunocytokines |
| Q57911975 | Immunocytokines |
| Q28066935 | Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site |
| Q38132742 | Immunocytokines: a review of molecules in clinical development for cancer therapy |
| Q50034069 | Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy |
| Q35059990 | NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy |
| Q64927862 | Radiotherapy in Combination With Cytokine Treatment. |
| Q38904873 | Synergistic immunologic targets for the treatment of prostate cancer |
| Q36552580 | T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein |
| Q90382339 | Targeting tumor cells with antibodies enhances anti-tumor immunity |
| Q37900640 | The role of inflammation in the pathogenesis of lung cancer |
| Q44703429 | Tumor necrosis therapy antibody interleukin-2 fusion protein elicits prolonged and targeted antitumor effects in vivo |
| Q38014920 | Using antibodies to target cancer therapeutics |
Search more.